Collegium Pharmaceutical, Inc (COLL)
| Market Cap | $790.25M-44.7% |
| Revenue (ttm) | $815.19M |
| Net Income | $38.17M |
| EPS | $1.09 |
| Shares Out | 31.08M |
| PE Ratio | 23.33 |
| Forward PE | 3.59 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 494,890 |
| Open | $25.68 |
| Previous Close | $25.32 |
| Day's Range | $25.04 - $25.68 |
| 52-Week Range | $21.43 - $50.79 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | $44.00(+73.02%) |
| Earnings Date | Nov 5, 2026 |
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
$COLL stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in COLL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by COLL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
COLL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
COLL Revenue by Segment
| Belbuca | $57.72M | 26.68% |
| Jornay PM | $51.86M | 23.97% |
| Xtampza ER | $45.82M | 21.18% |
| Azstarys | $26.52M | 12.26% |
| Nucynta IR | $16.72M | 7.73% |
| Nucynta ER | $9.91M | 4.58% |
| Nucynta ER AG | $3.88M | 1.79% |
| Symproic | $3.62M | 1.68% |
| Nucynta IR AG | $279.00K | 0.13% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New COLL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to COLL from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from COLL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Oppenheimer initiated COLL at Outperform with $50 PT and praised durable cash flow; analyst upgrades outweigh generic opinion pieces.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| SURI | Simplify Propel Opportunities ETF | 3.01% |
| PJP | Invesco Pharmaceuticals ETF | 2.72% |
| PBE | Invesco Biotechnology & Genome ETF | 2.42% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 2.08% |
| SIXS | ETC 6 Meridian Small Cap Equity ETF | 1.18% |
| MGMT | Ballast Small/Mid Cap ETF | 1.09% |
| RZG | Invesco S&P SmallCap 600 Revenue ETF | 0.63% |
| DSMC | Distillate Small/Mid Cash Flow ETF | 0.59% |
| HAPS | Harbor Human Capital Factor US Small Cap ETF | 0.56% |
| SFLO | VictoryShares Small Cap Free Cash Flow ETF | 0.51% |
| SCOW | Pacer Funds Trust - Pacer S&P SmallCap 600 Quality FCF Aristocrats ETF | 0.43% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.43% |
Weight is the stock’s share of each fund’s holdings.
